Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 study evaluating the safety, tolerability, and efficacy of BIVV003 in autologous hematopoietic stem cell trans…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• BIVV003

Snippet

Sponsor: Sangamo Therapeutics | Conditions: Sickle Cell Disease | Phase 1, Phase 2 | Status: COMPLETED